0001104659-24-063829 8-K 14 20240521 7.01 9.01 20240521 20240521 Annovis Bio, Inc. 0001477845 2834 03 Life Sciences 262540421 DE 1231 8-K 34 001-39202 24969308 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 QR Pharma, Inc. 20091202 8-K 1 tm2415055d1_8k.htm FORM 8-K false 0001477845 0001477845 2024-05-21 2024-05-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2024 ANNOVIS BIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-39202 26-2540421 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) File Number) Identification No.) 101 Lindenwood Drive, Suite 225 Malvern, PA 19355 (Address of Principal Executive Offices, and Zip Code) (484) 875-3192 Registrant’s Telephone Number, Including Area Code Not Applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value ANVS New York Stock Exchange $0.0001 per share Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company x If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ Item 7.01 Regulation FD Disclosure On May 21, 2024, Annovis Bio, Inc. (the “Company”) issued a press release dated May 21, 2024 which is being furnished as Exhibit 99.1 hereto. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release Dated May 21, 2024 104 Cover Page Interactive Data File SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: May 21, 2024 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer EX-99.1 2 tm2415055d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Annovis Announces New Publication in a Peer-Reviewed Journal MALVERN, Pa. -- May 21, 2024 -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen (or buntanetap) across different species in a peer-reviewed journal Biomolecules as part of the Special Issue: Role of Amyloid Protein in Neurological Diseases. “This publication is a testament to many years of research at Annovis. While we have conducted numerous studies to advance our Posiphen pipeline, this is the first systematic and comprehensive comparison in multiple animal and human samples," says Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "Consolidating all this data into one publication offers a more holistic view of Posiphen, enhancing our understanding of its mechanisms.” Title: Comparative Analysis of Posiphen Pharmacokinetics across Different Species—Similar Absorption and Metabolism in Mouse, Rat, Dog and Human Summary: This article synthesizes findings from various preclinical and clinical studies on Posiphen's absorption and metabolism from mice, rats, dogs, and humans. The aim was to better understand the differences in the drug’s pharmacokinetic behavior, identify which animal models most closely mimic human responses, and explore the potential clinical implications of these variations. Key highlights: · Posiphen quickly reaches peak concentration in plasma, followed by high absorption in the brain and cerebrospinal fluid (CSF). · Posiphen metabolizes into two primary metabolites: N1-norposiphen and N8-norposiphen. · Both Posiphen and its metabolites exhibit rapid clearance in animal models and human subjects; however, in the CSF or the brain, the drug stays longer. · Posiphen's absorption, distribution, metabolism, and excretion are similar in healthy volunteers and patients with Alzheimer’s and Parkinson’s diseases. The article can be found on the journal’s website via the link. About Annovis Bio, Inc. Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and other chronic neurodegenerative diseases. It is believed to be the only company developing a drug for both AD and PD designed to inhibit more than one neurotoxic protein to restore axonal and synaptic activity. By improving brain function, the company’s goal is to treat memory loss and dementia associated with AD as well as body and brain dysfunction associated with PD. For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and X (formerly known as Twitter). Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company advises caution in reliance on forward-looking statements. Forward-looking statements include, without limitation, the Company's plans related to clinical trials. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those implied by forward-looking statements, including regarding patient enrollment, the effectiveness of Buntanetap and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety and tolerability of buntanetap. See also additional risk factors set forth in the Company's periodic filings with the SEC, including, but not limited to, those risks and uncertainties listed in the section entitled "Risk Factors," in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC. All forward-looking statements in this press release are based on information available to the Company as of the date of this filing. The Company expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Investor Contact: Maria Maccecchini, Ph.D. maccecchini@annovisbio.com